NASDAQ:ANAB
AnaptysBio Inc Stock News
$23.94
+0.290 (+1.23%)
At Close: May 31, 2024
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
12:31pm, Tuesday, 22'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer
Merck & Co., Inc. (NYSE: MRK) s
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
08:15pm, Monday, 21'st Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
03:35pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
12:48pm, Tuesday, 15'th Mar 2022
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
12:07pm, Tuesday, 15'th Mar 2022 Benzinga
AnaptysBio Inc''s (NASDAQ: ANAB ) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events were reported. Based on the results, AnaptysBio will discontinue imsidolimab clinical development in acne. The primary endpoint of facial inflammatory lesion … Full story available on Benzinga.com
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
11:46am, Tuesday, 15'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne
Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
11:46am, Tuesday, 15'th Mar 2022 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB ) said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. The study will be discontinued. "Although the results of this ACORN trial are disappointing, I would like to thank all of the patients, investigators, staff and our employees involved in conducting this trial," said Hamza Suria , AnaptysBio''s CEO. "We look forward to further advancement of imsidolimab for the treatment of GPP and hidradenitis suppurativa. AnaptysBio continues to utilize its strong cash position in a capital-efficient manner to advance three wholly-owned clinical-stage programs with $90 to $100 million anticipated net cash burn in 2022." The stock was declining 10.48% to $25.46 in premarket trading. Biogen, Eisai Amend Economic Agreement Related To Aduhelm Biogen, Inc. (NASDAQ: BIIB ) and Eisai Co.
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
08:22am, Tuesday, 15'th Mar 2022
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally
AnaptysBio acne treatment imsidolimab fails in mid-stage trial
08:42pm, Monday, 14'th Mar 2022 Seeking Alpha
AnaptsBio (ANAB) acne treatment imsidolimab failed to demonstrate improvement compared to placebo in primary and secondary endpoints in a phase 2 trial. The company plans to…
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
08:20pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
03:05pm, Monday, 07'th Mar 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio GAAP EPS of -$1.18, revenue of $1.01M
02:04pm, Monday, 07'th Mar 2022 Seeking Alpha
AnaptysBio press release (ANAB): Q4 GAAP EPS of -$1.18.Revenue of $1.01M (+68.3% Y/Y).Shares -1.5% PM.
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
01:50pm, Monday, 07'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immu
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
05:45pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.